Loading organizations...
Loading organizations...

Holoclara: Biotechnology company developing nematode-derived therapeutics for allergic and autoimmune diseases, including asthma, type 1 diabetes, and IBD.
Holoclara, a cutting-edge biotechnology company based in Pasadena, California, was co-founded by CEO Andrea Choe, Caltech professor Paul W. Sternberg, and Cornell professor Frank C. Schroeder. They are dedicated to developing novel, orally available therapeutics derived from nematode secretions, specifically modulating inflammation, metabolism, and tissue regeneration to treat a range of allergic and autoimmune diseases like asthma, type 1 diabetes, and IBD. These safe, worm-derived drugs are currently being tested in preclinical mouse models, offering a unique approach without reintroducing live worms. The company recently completed an oversubscribed Series A financing round, successfully raising $16 million. This significant investment was led by BOLD Capital Partners, with key participation from Horizons Ventures, Freeflow Ventures, and Kairos Ventures, further strengthened by Peter Barton Hutt, former FDA Chief Counsel, joining the Board of Directors.
Holoclara has raised $16.0M across 1 funding round.
Holoclara has raised $16.0M in total across 1 funding round.
Holoclara is a biotechnology company developing safe, orally available therapies derived from gut roundworms (nematodes) to treat allergic and autoimmune diseases, such as asthma, type 1 diabetes, and inflammatory bowel disease (IBD).[1][2][4] It serves patients with these historically untreatable conditions by mining immunomodulatory molecules from worms, leveraging the hygiene hypothesis that worm presence historically protected against autoimmunity.[1][2] The company has raised $16 million in Series A financing led by BOLD Capital Partners, with participation from Horizons Ventures and angels, fueling preclinical advancement and a Phase 1 program started November 2024.[1][5]
Founded and led by physician-scientist Andrea Choe, Holoclara builds on decades of preclinical data showing worm-derived molecules' efficacy in calming immune responses.[1] The idea stems from the hygiene hypothesis: regions with intestinal roundworms had lower autoimmune rates until worm eradication in the 1900s coincided with disease rises, suggesting symbiotic co-evolution where worms produced protective secretions to evade immunity.[2][6] Early traction includes mouse model successes for asthma, type 1 diabetes, and IBD, backed by a team of worm biology and biotech experts, culminating in the 2024 Series A to translate this "longest-running drug program in history" into human therapies.[1][2][6]
Holoclara rides the autoimmune disease wave, addressing a market exploding due to modern hygiene, aging populations, and lifestyle shifts that fuel allergies and autoimmunity.[1][2] Timing aligns with advances in synthetic biology and immunomodulation, where worm-inspired therapies offer oral alternatives to injectables like biologics.[3][6] Favorable forces include rising unmet need (millions affected globally) and investor interest in bio-inspired platforms, positioning Holoclara to influence the ecosystem by validating nematode chemistry for broader applications beyond its initial indications.[1][4]
Holoclara's Phase 1 entry signals momentum toward first-in-class worm-derived drugs, with preclinical wins de-risking human proof.[5] Upcoming milestones include trial data readouts and potential expansion to metabolic/inflammatory targets, shaped by trends in precision immunomodulation and AI-accelerated drug discovery.[6] Its influence could grow by pioneering "symbiont-derived" biotech, challenging hygiene hypothesis skeptics and unlocking worm platforms for pharma giants—echoing how mRNA tech transformed vaccines, but for chronic immunity.
Holoclara has raised $16.0M in total across 1 funding round.
Holoclara's investors include Bold Capital Partners, AlleyCorp, Aniq Kassam, Lorie&co, Third Sphere.
Holoclara has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $16.0M Series A | Bold Capital Partners | AlleyCorp, Aniq Kassam, Lorie&co, Third Sphere |